Member Info for Strangy83

Nice to see you still have a sense of humor.

Was the chat removed?

21st?

In reality world though we are now nearing rerate time.

Well another meaningless post?

It arrives when it arrives and the we rerate

Not helped SP thus far today?

Now at

0.90p

At Windy.

Still a completely irritating and unlikely sealion.

Arf arf

Davey.

Remember you from. Some time ago and you were a constant ramper then.

So off you trot...

Yeboha.

I want the same as most investors, but your assumption that the media will be all over it has no foundations.

No media to date for anything so I think it will happen slowly as per JT post.

Would love to be proven wrong and Avacta really going to town with the data release.

But I am tempering my assumptions based upon what we know this far and the fact the the SP is very sluggish.

Apart from the Lion no one else seems to be able to answer why, we shall see in the coming weeks.

Hopefully

Probably best news for quite some time.

Yawn back.

Read the post and the relevance.

This is about a delivery mechanism that will soon be proven beyond doubt.

It will also include potentially lung cancer treatment long term for Avacta?

Simples

At Touk.

What the hell as relating Vital competitor trial failure have to do with other people's views about you.

I just posted info and you add my name somehow to the slanging match cos I started the thread. Are you that shallow?

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

The FTSE 100 pharmaceuticals giant said the trial aimed to address the treatment of patients with unresectable stage three non-small cell lung cancer (NSCLC) who either progressed or discontinued treatment during CRT, rendering them ineligible for the established 'PACIFIC' regimen, where Imfinzi is sequentially administered after platinum-based CRT.

Initial analysis of safety and tolerability for the concurrent administration of Imfinzi and CRT in the patient population revealed profiles broadly consistent with each treatment's known profiles.

Think Bella is incorrect and BV actually could be nearer the mark.

I am sure he stated it would take too long for a journal addition given the peer review timescales.

For FDA and investor comms IMO it will be a straight forward but in depth RNS.

This would need to be backed up be a sensational website update.

Also think we need the media coverage ramping up to get it mainstream once and for all.

Needs to be in general news and media outlets as transforming chemotherapy with no I'll health effects.

I think we are on the cusp and the next 4 weeks is pivotal and will be transformational.

Stay safe

Well there was a lot to read.

One especially from a councillor about her village.

I see this not being an issue given that the impact is seen as minor when looking at any other feedback about the project and site.

Lots of info went in at the end of Oct and beginning of Nov.

Well Yeboha.

I will go further.

I think the SP will either go up or down and may go up if there is good news. 🤣

At Thorn...

Conspiracy loony toon...

First arthritis and now a person who worked for Avacta.

What next...

I am an investor however Yeboha...

That is just another outlandish scenario that may also never play out.

Time will tell as will the data release in the next few weeks all being well.

Remember we only have a max of 40 working days until the Xmas break.

So the 40 day countdown to data is on...

Hope it is for you.

You talk utter drivel...

Https://fortune.com/2023/10/13/tempest-therapeutics-shares-surge-after-roche-led-cancer-treatment-trial/